Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s disease
Open Access
- 1 July 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Abstract
Almost all individuals with Down Syndrome (DS) develop Alzheimer’s disease (AD) by mid to late life. However, the degree to which AD in DS shares pathological changes with sporadic late-onset AD (LOAD) and autosomal dominant AD (ADAD) beyond core AD biomarkers such as amyloid-β (Aβ) and tau is unknown. Here, we used proteomics of cerebrospinal fluid from individuals with DS (n = 229) in the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) cohort to assess the evolution of AD pathophysiology from asymptomatic to dementia stages and compared the proteomic biomarker changes in DS to those observed in LOAD and ADAD. Although many proteomic alterations were shared across DS, LOAD, and ADAD, DS demonstrated more severe changes in immune-related proteins, extracellular matrix pathways, and plasma proteins likely related to blood-brain barrier dysfunction compared to LOAD. These changes were present in young adults with DS prior to the onset of Aβ or tau pathology, suggesting they are associated with trisomy 21 and may serve as risk factors for DSAD. DSAD showed an earlier increase in markers of axonal and white matter pathology and earlier changes in markers potentially associated with cerebral amyloid angiopathy compared to ADAD. The unique features of DSAD may have important implications for treatment strategies in this population.Keywords
This publication has 94 references indexed in Scilit:
- Characterization of white matter hyperintensities in Down syndromeAlzheimer's & Dementia, 2024
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- 2.Cerebrovascular neuropathology in the brains of people with Down syndromeAlzheimer's & Dementia, 2023
- Down Syndrome in a New Era for Alzheimer DiseaseJAMA, 2023
- Association of Alzheimer Disease With Life Expectancy in People With Down SyndromeJAMA Network Open, 2022
- Potential role of chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) in neurodegeneration and Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down SyndromeJAMA Neurology, 2021
- Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosisDevelopmental Neurobiology, 2019
- Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 YearsJAMA Neurology, 2019
- Incidence and impact of subclinical epileptiform activity in Alzheimer's diseaseAnnals of Neurology, 2016